General
Preferred name
TRIMETAZIDINE
Synonyms
TRIMETAZIDINE DIHYDROCHLORIDE ()
Kyurinett ()
Yoshimilon ()
Vastarel F ()
Trimetazidine (dihydrochloride) ()
Yoshimilon, Kyurinett, Vastarel F ()
Trimetazidine hydrochloride ()
Trimetazidine di-hcl ()
NSC-759317 ()
Trimetazidine hcl ()
Trimethazidine dihydrochloride ()
Dilatan ()
40045 ()
Vastarel MR ()
Vastarel ()
Trimetazidine (hydrochloride) ()
Trimetazidine-d8 (hydrochloride) ()
P&D ID
PD009144
CAS
5011-34-7
13171-25-0
127881-54-3
1219795-37-5
Tags
natural product
drug
available
First approval
1978
Drug Status
investigational
approved
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
19
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Mcule NIBR MoA Box Subset
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
47
Properties
(calculated by RDKit )
Molecular Weight
266.16
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
1
cLogP
1.12
TPSA
42.96
Fraction CSP3
0.57
Chiral centers
0.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Autophagy
Target
mitochondrial long-chain 3-ketoacyl thiolase
ACAA2
FAO
Member status
virtual
MOA
3-Ketoacyl-CoA Thiolase (3-KAT) Inhibitors
3-ketoacyl CoA thiolase inhibitor
Indication
angina pectoris
Source data
